HUTCHMED (China) (HCM) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perrigo (PRGO) has outperformed HUTCHMED (China) (HCM) over the past year, gaining 26.1% versus a loss of 5.6%. Over five years, PRGO leads with a -57.8% price change compared with -62.4% for HCM. HUTCHMED (China) is the larger company by market cap ($2.30 billion vs $2.21 billion), about 1.0 times the size, while Perrigo is growing revenue faster (-2.8% vs -13.0%).
On valuation, Perrigo trades at a lower forward P/E (6.9x vs 51.0x for HUTCHMED (China)). Perrigo pays a dividend yielding 7.28%, while HUTCHMED (China) does not currently pay one. HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -33.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | PRGO |
|---|---|---|
| Share price | $13.22 | $15.94 |
| Market cap | $2.30B | $2.21B |
| 1-day change | -1.71% | -0.62% |
| YTD return | -0.83% | +14.51% |
| 1-year return | -5.57% | +26.11% |
| 5-year return | -62.42% | -57.81% |
| P/E ratio (TTM) | 132.20 | — |
| Forward P/E | 51.00 | 6.94 |
| EPS (TTM) | $0.10 | $-12.47 |
| Dividend yield | 0.00% | 7.28% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | $548.51M | $4.25B |
| Revenue growth (YoY) | -12.96% | -2.75% |
| Net income (latest FY) | $456.91M | $-1.43B |
| Gross margin | 38.68% | 35.14% |
| Operating margin | -7.14% | -26.39% |
| Net margin | 83.30% | -33.51% |
| 52-week high | $16.33 | $17.07 |
| 52-week low | $9.77 | $9.23 |
| Distance from 52-week high | -19.04% | -6.62% |
| Analyst consensus | none | buy |
| Avg. price target upside | +59.91% | +12.92% |
| Average volume | 64.48K | 2.54M |
| Shares outstanding | 173.81M | 138.80M |
| Employees | 1,790 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRGO has outperformed HCM by 31.7 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -33.5 cents for Perrigo.
- Perrigo grew revenue faster in its latest fiscal year (-2.75% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
HCM vs PRGO FAQ
Which is bigger, HUTCHMED (China) or Perrigo?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.30B compared with $2.21B for Perrigo (PRGO).
Which stock has performed better over the past year, HCM or PRGO?
PRGO returned +26.11% over the past 12 months, compared with -5.57% for HCM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, HUTCHMED (China) or Perrigo?
Perrigo pays a dividend yielding 7.28%, while HUTCHMED (China) does not currently pay a regular dividend.
Are HUTCHMED (China) and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.